Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Eder

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated dailyJoseph P Eder, Jeffrey G Supko, Jeffrey W Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid TumorsSara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 1, 1997
High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomesC Wheeler, C Eickhoff, A Elias, et al.
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid TumorsJoaquin Mateo, Gopinath Ganji, Charlotte Lemech, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
ESMO Open|July 6, 2024
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortiumM V Lenti, D G Ribaldone, F Borrelli de Andreis, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated dailyJoseph P Eder, Jeffrey G Supko, Jeffrey W Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid TumorsSara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 1, 1997
High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomesC Wheeler, C Eickhoff, A Elias, et al.
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid TumorsJoaquin Mateo, Gopinath Ganji, Charlotte Lemech, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
ESMO Open|July 6, 2024
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortiumM V Lenti, D G Ribaldone, F Borrelli de Andreis, et al.
Pageof 12